Leerink Partnrs Analysts Raise Earnings Estimates for ALNY

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Equities researchers at Leerink Partnrs lifted their Q1 2025 earnings estimates for Alnylam Pharmaceuticals in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now expects that the biopharmaceutical company will post earnings of ($0.72) per share for the quarter, up from their prior estimate of ($0.74). The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals' Q2 2025 earnings at ($0.56) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($1.82) EPS.

Several other brokerages have also recently weighed in on ALNY. Morgan Stanley lowered their price target on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research report on Friday, April 11th. Redburn Atlantic started coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a "buy" rating and a $353.00 target price on the stock. Canaccord Genuity Group raised their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Finally, Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday, March 31st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $315.58.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded up $4.06 during midday trading on Friday, reaching $234.56. The stock had a trading volume of 601,349 shares, compared to its average volume of 872,674. The company has a market cap of $30.51 billion, a price-to-earnings ratio of -108.09 and a beta of 0.30. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39. The company's fifty day simple moving average is $249.14 and its 200 day simple moving average is $256.89. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03).

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Phillip A. Sharp sold 11,250 shares of the firm's stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the company's stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,234 shares of company stock valued at $19,958,097. Insiders own 1.50% of the company's stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Larson Financial Group LLC increased its stake in shares of Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares during the period. Park Square Financial Group LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth $28,000. Whipplewood Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 71 shares in the last quarter. R Squared Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $33,000. Finally, OFI Invest Asset Management acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $35,000. Institutional investors and hedge funds own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.